Natural Killer (NK) Cell

Natural Killer (NK) Cell designates a cytotoxic lymphocyte of the innate immune system capable of recognising and eliminating infected or malignant cells without prior antigen sensitisation, functioning through rapid immune surveillance and direct cell killing mechanisms. NK cells identify abnormal cells by integrating activating and inhibitory signals, triggering cytotoxic responses through perforin and granzyme release or death receptor pathways.

The biopharmaceutical industry increasingly targets NK cell biology for immuno-oncology and antiviral therapies, developing approaches that enhance NK activation, persistence, and tumour infiltration. Therapeutic strategies include monoclonal antibodies promoting antibody-dependent cellular cytotoxicity, cytokine therapies stimulating NK expansion, checkpoint blockade targeting inhibitory receptors, and engineered NK cell therapies. NK cells offer advantages including lower risk of graft-versus-host disease and potential for off-the-shelf allogeneic manufacturing. Manufacturing challenges include expansion to clinically relevant doses, maintaining functional potency, and ensuring consistent quality across batches. As engineering technologies improve and tumour microenvironment barriers become better understood, NK cell-based therapeutics continue advancing as promising immunotherapy modalities.